» Articles » PMID: 15932954

A Unified Model for Predicting Human Hepatic, Metabolic Clearance from in Vitro Intrinsic Clearance Data in Hepatocytes and Microsomes

Overview
Specialty Pharmacology
Date 2005 Jun 4
PMID 15932954
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CL(int, in vivo)) and hepatic clearance (CL(h)) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fu(b)) and in vitro incubations (fu(inc)). Human CL(int, in vivo) was projected using in vitro data together with biological scaling factors and compared with the unbound intrinsic clearance (CL(int, ub, in vivo)) estimated from clinical data using liver models with and without the various fu terms. For incubations conducted with fetal calf serum (n=14), the observed CL(int, in vivo) was modeled well assuming fu(inc) and fu(b) were equivalent. CL(int, ub, in vivo) was predicted best using both fu(b) and fu(inc) for other hepatocyte data (n=56; r(2)=0.78, p=3.3 x 10(-19), average fold error=5.2). A similar model for CL(int, ub, in vivo) was established for microsomal data (n=37; r(2)=0.77, p=1.2 x 10(-12), average fold error=6.1). Using the model for CL(int, ub, in vivo) (including a further empirical scaling factor), the CL(h) in humans was also calculated according to the well stirred liver model for the most extensive dataset. CL(int, in vivo) and CL(h) were both predicted well using in vitro human data from several laboratories for acidic, basic, and neutral drugs. The direct use of this model using only in vitro human data to predict the metabolic component of CL(h) is attractive, as it does not require extra information from preclinical studies in animals.

Citing Articles

Comprehensive benchmarking of computational tools for predicting toxicokinetic and physicochemical properties of chemicals.

Gadaleta D, Serrano-Candelas E, Ortega-Vallbona R, Colombo E, Garcia de Lomana M, Biava G J Cheminform. 2024; 16(1):145.

PMID: 39726044 PMC: 11674477. DOI: 10.1186/s13321-024-00931-z.


Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention.

Nie Z, Bonnert R, Tsien J, Deng X, Higgs C, El Mazouni F J Med Chem. 2024; 68(1):590-637.

PMID: 39710971 PMC: 11726676. DOI: 10.1021/acs.jmedchem.4c02394.


In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β-Isomer Propylene Glycol Methyl Ether.

Werner S, Hegg L, Hopf N, Borgatta M, Suter-Dick L Pharmacol Res Perspect. 2024; 12(6):e70037.

PMID: 39655648 PMC: 11629119. DOI: 10.1002/prp2.70037.


Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria.

Lawong A, Gahalawat S, Ray S, Ho N, Han Y, Ward K Cell Chem Biol. 2024; 31(8):1503-1517.e19.

PMID: 39084225 PMC: 11531662. DOI: 10.1016/j.chembiol.2024.07.001.


Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans.

Geci R, Gadaleta D, Garcia de Lomana M, Ortega-Vallbona R, Colombo E, Serrano-Candelas E Arch Toxicol. 2024; 98(8):2659-2676.

PMID: 38722347 PMC: 11272695. DOI: 10.1007/s00204-024-03764-9.